In breast cancer, ZDHHC9 enhances PD-L1 stability through palmitoylation [112, 113], and ZDHHC9 deficiency in lung cancer prevents PD-L1 degradation, enhancing the effectiveness of anti-PD-L1 immunotherapy [115]. The gene discussed is ZDHHC9; the disease is breast carcinoma.